Teladoc Health Inc.'s stock plummeted 5.07% during intraday trading on Thursday, reflecting investor concerns ahead of the company's upcoming first-quarter earnings report.

The decline follows an earnings preview indicating expected Q1 revenue of $611.38 million, a 1.26% year-over-year decrease, with forecast adjusted EPS of -$0.313 and EBIT loss of $53.73 million. Institutional commentary has been cautious to bearish, highlighting slowing enterprise demand, a tempered revenue outlook, and an elongated path to sustained profitability, which has dampened investor sentiment.